Physician profile
Barry D Harris
NPI 1922054170
$4,964.14
in general payments reported to CMS, 2019-2025
39 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $422 · 2021: $658 · 2022: $1,271 · 2023: $835 · 2024: $549 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $613.12 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $416.70 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.60 | 2019-2025 | Jardiance |
| Pfizer INC. | $353.69 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $333.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $316.86 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $313.73 | 2020-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $244.68 | 2022-2025 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $241.54 | 2019-2022 | |
| Novo Nordisk INC | $237.52 | 2023-2025 | Ozempic, Wegovy |
| Medtronic, INC. | $224.48 | 2021-2025 | Closurefast |
| Abbott Laboratories | $221.62 | 2022-2025 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $213.31 | 2019-2024 | Lifevest |
| Cvrx, INC. | $167.88 | 2023-2025 | Barostim Neo System |
| Boston Scientific Corporation | $96.64 | 2021-2025 | General - Therapies |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $87.88 | 2021-2025 | Opsumit |
| Philips North America LLC | $65.36 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Esperion Therapeutics, INC. | $61.25 | 2021-2025 | Nexletol |
| Medicomp INC | $46.10 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $44.60 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $44.19 | 2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $34.13 | 2019-2020 | |
| Akcea Therapeutics, INC. | $28.00 | 2019 | |
| Edwards Lifesciences Corporation | $26.07 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $24.45 | 2023 | Arcalyst |
| Vital Connect, INC | $22.46 | 2025 | Vitalpatch Rtm |
| Altathera Pharmaceuticals LLC | $19.59 | 2025 | Sotalol Hydrochloride |
| Baxter Healthcare | $19.57 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $18.42 | 2019 | |
| Lilly USA, LLC | $16.75 | 2023 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $15.33 | 2023 | Inpefa |
| Sobi, INC | $15.31 | 2021 | |
| Inspire Medical Systems, INC. | $15.23 | 2025 | Inspire |
| Bardy Diagnostics, INC. | $5.00 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.